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Abstract
Opioids are increasingly used for treatment of chronic pain. However, they are only effective
in a subset of patients and have multiple side effects. Thus, studies using biomarkers for
response are highly warranted. The current study prospectively examined 63 opioid-naïve
patients initiating opioid use for diverse types of chronic pain at five European centers.
Quantitative sensory testing, electroencephalography (EEG) recordings, and assessment
of pain catastrophizing were performed prior to treatment. The co-primary outcomes were
change from baseline in ratings of chronic pain and quality of life after 14 days of opioid treat-
ment. Secondary outcomes included patient’s global impression of clinical change and side
effects. Logistic regression models adjusted for age and sex were used to identify biomark-
ers predictive for successful treatment, defined as at least a 30% reduction in average pain
intensity or an improvement in quality of life of at least 10 scale points. Fifty-nine patients
(94%) completed the study. The mean age was 55 ± 16 years and 69% were females. Pain
reduction was predicted by cold pain intensity (OR: 0.69; P = 0.01), pain catastrophizing
(OR: 0.82; P = 0.03), relative delta (OR: 0.76; P = 0.03) and beta EEG activity (OR: 1.18;
P = 0.04) induced by experimental cold pain. None of the study variables were related to
improvement in quality of life. For the first time, individual pain processing characteristics
have been linked to opioid response in a mixed chronic pain population. This has the poten-
tial to personalize treatment of chronic pain and restrict opioid use to patients with high likeli-
hood for response.
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Introduction
Chronic pain is a highly prevalent condition that may impact negatively on the individual’s
quality of life; moreover, it is an expensive condition for society. Presently, chronic pain is con-
sidered as a bio-psychosocial phenomenon–a combination of physical dysfunction, beliefs,
coping strategies, distress, illness behavior and social interactions. Pharmacotherapy is a cor-
nerstone in the multimodal interdisciplinary treatment. However, chronic pain treatment still
largely depends on local experience and traditions rather than individual patient characteris-
tics [1, 2]. Chronic pain treatment, usually involving more than one drug, is seldom adjusted
according to individual treatment response, but rather escalated or several therapies are tried
in turn. Unfortunately, this strategy often leads to insufficient pain control, intolerable side
effects, and psychosocial distress [3]. A deep concern has recently been raised about the uncrit-
ical prescription of opioids leading to growing abuse, addiction, and overdoses in the US [4].
Up to 50% of patients treated with morphine experience inadequate analgesia, despite escalat-
ing dose and/or experience intolerable or dose-limiting side effects [1]. This has driven a dis-
covery-oriented research for biomarkers that can predict treatment response. However, due to
the complexity of chronic pain, this approach has failed in clinical practice. Quantitative sen-
sory testing, electroencephalography (EEG) recordings, and coping strategies have previously
been used to identify patient subgroups in experimental studies and in highly selected chronic
pain populations [5–8]. This includes morphine response in healthy volunteers, duloxetine
efficacy in painful diabetic neuropathy, and pregabalin efficacy in painful chronic pancreatitis
[9–11]. However, no studies have yet examined whether individual pain processing can predict
efficacy of unselected opioids in a mixed patient population with chronic pain.
We hypothesized that the most promising techniques in previous experimental, postoperative,
and clinical pain studies could serve as biomarkers of chronic pain and opioid analgesia. Hence,
the objective of this study was to determine whether characteristics of altered pain processing in
opioid-naïve patients could be used to predict clinically relevant treatment responses to opioids.
To ensure general applicability, we collected longitudinal data from heterogeneous patient popula-
tions with moderate to severe chronic pain initiating opioid use at five centers in Europe.
Methods
Study design
The Predictive Markers of the Effects of Opioid Therapy in Opioid-naïve Patients with Chronic
Pain (ABILITY) study was a two-week observational cohort study designed to evaluate the pre-
dictive value of pre-treatment markers of opioid response in opioid-naïve patients with various
chronic pain conditions. This study was conducted across outpatient clinics at four university
hospitals and one private hospital in Denmark, Slovenia, and Belgium. The research team
recruited participants and conducted follow-up from October 2014 to September 2015. Opioid
treatment of study patients took place without randomization and followed clinical practice at
each participating center to reflect the true clinical situation. Opioid treatment was deter-
mined, prescribed, modified and discontinued at the sole discretion of the treating physician
at each participating center; regardless of generic name, manufacturer, constituent compo-
nents, route of administration, and dosing schedule (including titration and run-in periods).
Regardless of any decision to modify or discontinue their assigned opioid treatment, study
subjects were retained in the study whenever possible to enable follow-up data collection and
prevent missing data. Of note, previously used pain medications were continued throughout
the study. If opioid treatment was discontinued as a result of an adverse event, the circum-
stances leading to discontinuation of treatment were documented.
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Ethics statement and study registration
The Central Denmark Region Committees on Health Research Ethics (1-10-72-132-14) and
the Danish Data Protection Agency (1-16-02-300-14/2007-58-0010) approved the study. The
study protocol was further approved by the local ethics committees at each participating cen-
ter. Participation in the study had no impact on the patients’ current or subsequent care and
treatment. All study participants gave written informed consent. No financial compensation
was given at any time during study. The study is registered at the US National Institutes of
Health (ClinicalTrials.gov) #02308306.
Data collection and follow-up
Patient demographics, medical history and medications, persistent pain features, quantitative
sensory testing, EEG, and situational pain catastrophizing were registered and assessed at base-
line. Data on clinical efficacy and side effects were collected at 14-days after initiating opioid
treatment using a mailed questionnaire.
Patients
The following main inclusion criteria were used: Pain duration3 months; baseline pain
intensity4 and<9 on an 11-point numerical rating scale (NRS) ranging from 0 (no pain) to
10 (worst pain imaginable); expected to continue opioid and any concomitant non-opioid
treatment throughout the study and age>18 years. Exclusion criteria were: Mental incapacity
or language barriers precluding adequate understanding of study procedures; significant seri-
ous underlying conditions or similar reasons; having received opioid(s) on a daily basis (within
the last 10 weeks); current alcohol and/or substance abuse.
Outcome measures
The change from baseline in ratings of Brief Pain Inventory average pain scale (NRS 0–10)
[12] and European Organization for Research and Treatment of Cancer Quality of Life ques-
tionnaire (QLQ-C30) health-related quality of life scores (0–100) [13] were chosen as co-pri-
mary efficacy endpoints in accordance with the Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) recommendations [14, 15]. A clinically successful
treatment response was defined as a pre-specified reduction in average pain intensity level
above baseline, i.e., at least 30% (moderate to substantial improvement) [16, 17]. Similarly, a
subjectively significant (moderate) change in quality of life scores was defined as10 from
baseline [18]. Secondary outcomes included change from baseline in ratings of the Brief Pain
Inventory pain intensity items, patient-reported global impression of clinical change and
adverse events.
Predictors of clinically successful opioid treatment
Quantitative sensory testing. Electrical pain sensitivity was assessed on the volar forearm
2 cm distal to the wrist using a computer-controlled constant current stimulator (Isolator
Stimulator Noxi IES 230, JNI Biomedical, Klarup, Denmark). The current intensity was gradu-
ally increased in steps of 1 mA until a sensation of pain was evoked (electrical pain detection
threshold). Pressure pain sensitivity was assessed at the subjects’ quadriceps muscle 10 cm
above the patella on the same side as the dominant hand using a handheld digital pressure alg-
ometer with a probe size of 1 cm2 (Algometer, Somedic AB, Ho¨rby, Sweden). Pressure was
gradually increased with a rate of 30 kPa per second until a pain sensation was evoked (pres-
sure pain detection threshold). Cold pressor pain was induced by immersion of the patient’s
Predictors of opioid efficacy
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hand in a stirred ice water bath (1–2˚C) for two minutes. Patients were asked to rate worst
cold pressor pain intensity (NRS 0–10) after two minutes of hand immersion (or upon sponta-
neous hand removal) and the pressure pain detection threshold was reassessed. The condi-
tioned pain modulation effect was defined as the relative change in pressure pain thresholds
before and after the cold pressor test. In brief, the ice water (conditioning stimulus) typically
results in pain inhibition to the second pressure stimulus [19].
Electroencephalography recordings. Electrical activity of the brain was recorded during
the two-minute cold pressor test via an electrode head cap with premeasured electrode place-
ment (BIONEN Medical Devices, Firenze, Italy) using a digital amplifier (NuAmps, Neuros-
can, El Paso, Texas, USA). Nine electrode sites and a reference electrode site were filled with
Electro-Gel (Electro-Cap International, Eaton, OH, USA) and prepped to measured imped-
ance values below 5 kohms. Pre-processing and spectral analysis of EEG dynamics have been
described in detail elsewhere [10]. In brief, the absolute values of the obtained wavelet coeffi-
cients were used for analysis and divided into the following standardized frequency bands:
Delta (1–4 Hz), theta (4–8 Hz), alpha (8–12 Hz) and beta (12–32 Hz). The wavelet coefficients
were averaged over time and scales contained within each frequency band were summed
together. The relative activity was then calculated separately for each channel by dividing each
frequency band with the total energy of all bands and multiplying by 100; values then repre-
sented the percentage of total amplitude contained in each frequency band.
Situational pain catastrophizing. In connection with quantitative sensory testing,
patients completed the Pain Catastrophizing Scale with reference to the pain induced by the
cold pressor test [20]. Original instructions were appropriately revised [21]. Pain catastrophiz-
ing is characterized as the tendency to magnify the threat value of a pain stimulus and to feel
helpless in the context of pain, and by a relative inability to inhibit pain-related thoughts in
anticipation of, during or following a painful event [21].
Study sample size
To date, no study has identified pre-treatment measures of opioid efficacy in opioid-naïve
patients initiating opioid use for chronic pain and no a priori sample size could be calculated.
The selection of clinically implementable measures for predicting opioid efficacy was therefore
based on experiences from numerous clinical studies and by reviewing available literature [5].
We aimed at a sample size of 60 patients.
Statistical methods
Analyses included all patients who took at least one dose of opioid medication and had at least
one post-treatment efficacy assessment (complete case), irrespective of whether they continued
opioid and any concomitant non-opioid treatment throughout the study or stopped treatment
prematurely. Repeated outcome measurements and baseline characteristics between patients
with and without clinically successful treatment were compared using the Wilcoxon signed-
rank test and the Wilcoxon rank-sum test, respectively. Multilevel mixed-effects logistic
regression models with a random intercept by participating center identification were applied
to examine the influence of selected pre-treatment measures on opioid response. In brief,
mixed effects logistic regression is used to model binary outcome variables when data are clus-
tered or there are both fixed and random effects. In this study, a variety of outcomes were col-
lected on patients, who were nested within clinics. By taking clustering within clinics into
account, odds ratios (OR) and 95% confidence intervals (95% CI) were calculated with and
without adjustment for sex and age. Concerning continuous predictors, it should be noted that
the coefficient is the odds ratio for successful treatment per unit of measurement of difference
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in the explanatory variable. Two-tailed P-values<0.05 were considered statistically significant.
Stata/IC 12.1 (StataCorp LP, College Station, TX, USA) was used for all statistical analyses.
Results
The five participating centers screened 73 patients for eligibility (Fig 1). A total of 63 patients
were enrolled and examined at baseline; 59 patients (94%) completed the post-treatment follow-
up assessment. Demographic and baseline characteristics of patients are depicted in Table 1.
Outcomes
Table 2 shows changes in primary and secondary outcomes after 14-days of opioid treatment.
Treatment was clinically successful in nine patients (16%) where average pain intensity was
Fig 1. Flowchart. Numbers of patients screened for eligibility, examined, and analyzed for primary outcome.
doi:10.1371/journal.pone.0171723.g001
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Table 1. Demographic and baseline characteristics of patients.
Clinical variables
Participating center, number of participants
Aarhus, DK 7 (12)
Leuven, BE 3 (5)
Ljubljana, SLO 17 (29)
Ringsted, DK 18 (31)
Give, DK 14 (24)
Sex (female/male) 41/18 (69/31)
Age, years 55 ±16
Weight, kg 79 ±17
Height, cm 171 ±10
BMI, kg/m2 27 ±5
Obese, BMI>30 15 (25)
Hand dominance (right/left) 56/3 (95/5)
Educational status
Higher 6 (10)
Secondary 37 (63)
Basic 16 (27)
Employment status
Employed 12 (20)
Unemployed 16 (27)
Retired 25 (42)
Other 6 (10)
Marital status (living with partner/alone) 47/11 (81/19)
Main site of pain
Head, face, and mouth 2 (3)
Cervical region 6 (10)
Shoulder and upper limbs 14 (24)
Thoracic region 3 (5)
Lower back, lumbar spine, sacrum, coccyx 19 (32)
Lower limbs 7 (12)
More than three major sites 8 (14)
Abnormal system functioning producing pain
Nervous system (CNS, PNS, autonomic) 28 (47)
Musculoskeletal system and connective tissue 30 (51)
More than one system 1 (2)
Temporal characteristics of pain
Continuous, nonfluctuating 26 (44)
Continuous, fluctuating severity 31 (53)
Recurring irregularly 1 (2)
Recurring regularly 1 (2)
Patient’s statement of pain intensity
Medium—1 to 6 months 6 (10)
Medium—more than 6 months 15 (25)
Medium—1 month or less 1 (2)
Severe—1 to 6 months 5 (8)
Severe—more than 6 months 31 (53)
Unknown 1 (2)
(Continued )
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reduced by at least 30%; 12 patients (21%) demonstrated a clinically relevant change (score
10 from baseline) in quality of life assessed by QLQ-C30. Eleven patients (19%) stopped opi-
oid treatment prematurely. The most frequently reported side effect was sedation (74%) fol-
lowed by constipation (49%), nausea (46%), and dry mouth (44%).
Table 1. (Continued)
Clinical variables
Etiology
Genetic or congenital disorders 3 (5)
Trauma, operation, burns 19 (32)
Infective, parasitic 1 (2)
Inflammatory 4 (7)
Neoplasm 1 (2)
Degenerative, mechanical 23 (39)
Unknown or other 8 (14)
Non-opioid analgesic pre-treatment
No treatment 20 (34)
NSAIDs 10 (17)
PCM 18 (31)
NSAIDs + PCM 11 (19)
Adjuvant analgesic pre-treatment
No treatment 41 (69)
Antidepressants 6 (10)
Anticonvulsants 3 (5)
Muscle relaxants 2 (3)
Others 3 (5)
Antidepressants + anticonvulsants 2 (3)
Anticonvulsants + muscle relaxants 2 (3)
Quantitative sensory testing
Electrical pain threshold, mA 15 [5; 28]
Pressure pain threshold, kpA 1077 [737; 1436]
Cold pressor time, sec 103 [37; 120]
Cold pressor pain, NRS 0–10 8 [5; 10]
Conditioned pain modulation, kpA 80 [-5; 211]
Conditioned pain modulation, relative values 7 [-1; 21]
Situational pain catastrophizing 27 [11; 36]
Prescribed opioid treatment
Tramadol 24 (41)
Methadone 3 (5)
Oxycodone 4 (7)
Morphine 1 (2)
Buprenorphine 24 (41)
Tapentadol 3 (5)
Morphine milligram equivalents per day (mg/day) 10 [10; 10]
Values are presented as numbers (%), means ± SD or medians [interquartile range], as appropriate.
BMI: Body Mass Index; CNS: Central Nervous System; PNS: Peripheral Nervous System; NSAIDs: Non-
steroidal Anti-inflammatory Drugs; PCM: paracetamol (acetaminophen).
doi:10.1371/journal.pone.0171723.t001
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Predictors of clinically successful treatment
Mixed-effects logistic regression output are shown in Table 3. These analyses indicated that
clinically successful treatment in terms of average pain reduction to opioid treatment was asso-
ciated with cold pain intensity (OR: 0.69; 95% CI: 0.53 to 0.90; P = 0.01), pain catastrophizing
(OR: 0.82; 95% CI: 0.68 to 0.98; P = 0.03), relative delta (OR: 0.76; 95% CI: 0.59 to 0.97; P =
0.03) and beta EEG activity (OR: 1.18; 95% CI: 1.01 to 1.37; P = 0.04) induced by experimental
cold pain. In contrast, none of the study variables were predictive of improvement in quality of
life (Table 3).
Discussion
In this cohort study on a heterogeneous study population of patients with various chronic pain
conditions and different underlying pain mechanisms, initiating use of both weak and strong
opioids, we found evidence to support the hypothesis that opioid efficacy can be predicted
before treatment based on patients’ responses to experimental pain. Our results suggest that
patients with a relative ability to inhibit pain-related thoughts and feelings, reporting lower
Table 2. Changes in primary and secondary outcomes after 14-days of opioid treatment.
Outcome Pretreatment score (95% CI) 14-days change (post-pre) (95% CI) P value
BPI
Worst pain 7.2 (6.8; 7.6) -0.3 (-0.6; 0.03) 0.12
Mild pain 4.3 (3.8; 4.8) 0.2 (-0.3; 0.6) 0.47
Average pain 6.1 (5.7; 6.5) -0.3 (-0.7; 0.05) 0.11
Current (now) pain 5.7 (5.2; 6.3) -0.2 (-0.8; 0.3) 0.60
Mean severity score 5.8 (5.4; 6.2) -0.2 (-0.5; 0.2) 0.71
Mean interference score 5.9 (5.4; 6.4) -0.7 (-1.2; -0.2) 0.02
QLQ-C30
Global health status 55.6 (50.6; 60.6) 2.9 (-1.9; 7.7) 0.39
Physical functioning 49.7 (45.0; 54.4) 2.1 (-1.4; 5.7) 0.13
Role functioning 37.5 (30.3; 44.6) -0.3 (-6.8; 6.2) 0.80
Emotional functioning 56.9 (50.0; 63.9) 8.9 (-4.9; 12.8) <0.0001
Cognitive functioning 51.4 (43.2; 59.7) 4.6 (-0.3; 9.5) 0.08
Social functioning 51.4 (43.5; 59.4) 8.6 (-2.7; -14.4) 0.007
Fatigue 65.4 (59.4; 71.4) -5.2 (-10.4; 0.1) 0.05
Nausea and vomiting 9.3 (4.8; 13.8) 5.9 (-0.3; -11.6) 0.15
Pain 79.4 (74.5; 84.3) -6.8 (-12.3; -1.3) 0.03
Dyspnea 14.9 (9.0; 20.9) 2.9 (-3.1; 8.9) 0.57
Insomnia 61.5 (52.8; 70.2) -10.3 (-17.2; -3.5) 0.009
Appetite loss 20.3 (12.8; 27.9) -2.8 (-9.1; 3.5) 0.31
Constipation 14.4 (8.4; 20.3) 8.0 (1.0; 15.1) 0.05
Diarrhea 10.5 (5.2; 15.9) -4.1 (-9.1; 0.9) 0.06
Financial difficulties 43.0 (32.7; 53.4) -6.1 (-13.0; 0.9) 0.03
Changes in primary and secondary outcomes with 95% confidence intervals (95% CI) after 14-days of opioid treatment.
95% CI: 95% Confidence Interval; BPI: Brief Pain Inventory; Mean severity score: A composite of the four BPI pain items; Mean interference score: A
composite of the seven BPI pain interference items; QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life questionnaire,
each QLQ-C30 scale score ranges from 0–100. A higher score for global health status/quality of life indicates a high quality of life; a higher score for
functional scales indicates a healthy level of functioning; and a high score on the symptom scale and on single items indicates a high level of symptoms or
problems.
doi:10.1371/journal.pone.0171723.t002
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pain intensity ratings, or expressing specific electrical brain activity patterns during painful
stimulation benefit most from opioid treatment.
There is emerging evidence from experimental pain studies that nociceptive characteristics
can serve as predictors of treatment response [5]. Further, a few clinical studies have evaluated
the role of pain processing in the prediction of clinically successful chronic pain treatment, but
only in highly selected patient populations [9, 11]. Yarnitsky et al. showed that duloxetine, a
serotonin-norepinephrine reuptake inhibitor (SNRI) believed to improve a malfunctioning
pain modulation mechanism, was most beneficial in alleviating the pain in patients with pain-
ful diabetic neuropathy demonstrating inefficient conditioned pain modulation [9]. Olesen
et al. found that patients with pain due to chronic pancreatitis with segmental hyperalgesia of
the pancreatic viscerotome had a superior pregabalin response [11]. Our finding that the cold
pressor pain response predicted opioid treatment response further stresses the potential of
Table 3. Associations of pre-treatment predictive factors with measures of clinically successful treatment.
Model 1 Unadjusted Model 2 Adjusted
Outcome/Predictors OR SE P value 95% CI OR SE P value 95% CI
Δ BPI Average pain30%
EPT 1.03 0.03 0.33 0.97–1.10 1.03 0.03 0.39 0.97–1.10
PPT 1.00 0.001 0.41 0.99–1.01 1.00 0.001 0.66 0.99–1.01
CPT time 1.00 0.01 0.38 0.99–1.03 1.00 0.01 0.56 0.98–1.03
CPT pain 0.69 0.1 0.01 0.52–0.92 0.69 0.09 0.01 0.53–0.90
CPM% 0.99 0.02 0.74 0.97–1.02 0.99 0.02 0.62 0.96–1.02
S-PCS 0.85 0.05 0.01 0.75–0.96 0.82 0.09 0.03 0.68–0.98
EEG delta activity 0.80 0.08 0.02 0.67–0.97 0.76 0.10 0.03 0.59–0.97
EEG theta activity 0.87 0.19 0.54 0.56–1.35 0.92 0.20 0.70 0.59–1.43
EEG alpha activity 1.01 0.12 0.44 0.88–1.33 1.28 0.21 0.14 0.93–1.77
EEG beta activity 1.18 0.09 0.03 1.02–1.37 1.18 0.09 0.04 1.01–1.37
Δ QLQ-C30 Global health status10
EPT 1.01 0.03 0.62 0.96–1.06 1.01 0.03 0.97 0.97–1.07
PPT 1.00 0.001 0.53 0.99–1.01 1.00 0.001 0.34 0.99–1.01
CPT time 1.00 0.01 0.56 0.99–1.01 1.00 0.01 0.68 0.98–1.01
CPT pain 0.86 0.09 0.18 0.70–1.07 0.87 0.09 0.20 0.70–1.08
CPM% 1.01 0.01 0.40 0.99–1.03 1.01 0.01 0.40 0.99–1.03
S-PCS 1.00 0.02 0.90 0.96–1.05 1.01 0.03 0.77 0.96–1.06
EEG delta activity 0.95 0.06 0.38 0.84–1.07 0.89 0.07 0.17 0.76–1.05
EEG theta activity 0.87 0.18 0.49 0.58–1.30 0.76 0.19 0.27 0.47–1.23
EEG alpha activity 1.05 0.10 0.66 0.86–1.27 1.05 0.14 0.72 0.81–1.36
EEG beta activity 1.05 0.06 0.40 0.93–1.18 1.10 0.07 0.16 0.96–1.25
Associations of pre-treatment predictive factors with measures of clinically successful treatment (average pain intensity reduction30% and global health
status improvement10), estimated odds ratios (OR) with 95% confidence intervals (95% CI) from multilevel mixed-effects logistic regression models.
Model 1: unadjusted mixed-effects logistic regression model including only the predictor variable of interest (as continuous variable) and a random intercept
for participating center as explanatory variables; Model 2: mixed-effects logistic regression model including additional adjustment for sex (as dichotomous
variable) and age (as continuous variable). Of note, concerning continuous predictors, the coefficient is the odds ratio for successful treatment per unit of
measurement of difference in the predictor variable; OR: odds ratio; SE: standard error; 95% CI: 95% Confidence Intervals; Significant P values are marked
in bold; BPI: Brief Pain Inventory; EPT: Electrical pain threshold (mA); CPM%: conditioned pain modulation (i.e. relative (%) difference between two test
stimuli (pressure pain thresholds—PPT) before and after a conditioning stimuli (120 s cold pressor test—CPT) (last minus first); S-PCS: the Situational Pain
Catastrophizing Scale administered in connection with CPT; relative delta (1–4 Hz), theta (4–8 Hz), alpha (8–12 Hz) and beta (12–32 Hz) bandwidth
activities; QLQ-C30: European Organization for Research and Treatment of Cancer.
doi:10.1371/journal.pone.0171723.t003
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using quantitative sensory testing in routine clinical practice. Brain function is a promising
biomarker for chronic pain and a neural signature of experimental pain has recently been
defined in humans [22]. EEG recorded as evoked brain potentials has proven a viable tool for
analyzing changes in cortical activity following administration of different analgesics [2, 23].
Specifically the activity in the delta band was changed in experimental and clinical studies fol-
lowing opioid administration [24]. In experimental studies the EEG response to experimental
pain was also shown to predict the effect of morphine and the delta band was the main fre-
quency band involved in differentiating between responders and non-responders to morphine
analgesia [10]. This was also the case in the present study and thus it seems the delta band is
closely connected to opioid analgesia, and thus a possible biomarker to be used in personalized
clinical pain management interventions. The fact that the beta band also predicted successful
opioid treatment has not been reported in previous studies. However, as relative EEG indices
are used there is a chance that differences in the delta band could carry over to the beta band.
Nonetheless, the beta band should be further investigated for its ability to predict pain and
analgesia, as it has previously been shown to be involved in pain processing [25]. EEG might
be a particularly interesting technology because it makes little demands on patients’ cognition
and cooperation. Moreover, reliable EEG is now easily recorded using cheap commercial
headsets, thus facilitating more widespread clinical use [26]. Typically, patients with high levels
of pain catastrophizing rate their pain higher than non-catastrophizers. As such, catastrophi-
zers are more likely than non-catastrophizers to continue to suffer from high levels of persis-
tent pain in spite of treatment [27]. We aimed at investigating pain catastrophizing with
reference to cold pressor pain, because more robust correlations with pain-related outcomes
have been reported for situational measures of pain catastrophizing compared with disposi-
tional measures [21, 28, 29]. The mechanism by which pain catastrophizing interferes with
analgesic treatment response is unclear, but there is evidence to suggest that it may be related
to a disruption in the endogenous modulation of pain [30]. Pain catastrophizing shares vari-
ance with negative affect constructs, such as anxiety and depression; other psychological tests
might also have been suitable to elucidate a patient’s pain and inform pain-treatment strate-
gies. However, we anticipated that additional questionnaires would only complicate and
increase the length and difficulty of testing without necessarily producing better treatment
prediction.
There are limitations to our study. The study was intentionally observational and represen-
tative of the real-world sample in order to mirror the daily clinical setting. Hence, we acknowl-
edge, that our study group was very varied, representing many chronic pain related diseases
and conditions that could all have influenced the treatment responses to opioids. Along this
line, it is worth mentioning that, multiple pain mechanisms and outcome-relevant patient
characteristics may be active to varying degrees in different patients within a chronic pain
related disease or condition–leading to marked inter-subject variation in treatment effects
[31].This variability in phenotypic presentation of different chronic pain related diseases and
conditions has been found to be greater between patients than between different chronic pain
related diseases and conditions [32–34], indicating that successful treatment is likely to be
based at the level of the individual rather than at the level of the disease [31]. Furthermore,
focusing on a single pain related disease or condition would have limited the generalizability
of the study and reduced the sample size that could be achieved in the available study period. It
is also worth mentioning that some patients will benefit from any type of intervention you
offer. Thus we cannot exclude that multimodal treatment approaches usually involving more
than one drug or even a placebo treatment would have had the same effect. Future studies
might further standardize concurrent interdisciplinary treatment to clarify if our findings are
specific enough for opioids. Another limitation is the lack of long-term follow-up. How this
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might affect prediction of the efficacy of a longer-term opioid prescription with a fixed mode
of administration/dose is debatable. It is also uncertain whether our results can be generalized
to all opioids. Our opioid response may seem low; however complete pain relief is unlikely and
we may have set the threshold too high by defining a response as30% pain relief. Based on
the observed change from baseline in ratings of BPI pain interference items and QLQ-C30
functional scales, we found some evidence that opioids improved function; however, the num-
ber of reported side effects mostly supports the extensive evidence showing the possible harms
of opioids. There are diseases and clinical circumstances under which improvement in physi-
cal function is a more realistic goal than reductions in pain and vice versa. Nonetheless, a sin-
gle outcome measure including improvement in both pain relief and function is highly
warranted.
In summary, the analgesic action of opioids remains unpredictable whereas most patients
suffer from side effects. Hence, there is an unmet need for more personalized clinical interven-
tions in pain management. Our results show that alterations in pain regulatory systems may be
linked to successful chronic pain treatment. Our data also suggest that a test battery to investi-
gate pain processing can easily be implemented in daily practice and may pave the road for
improved pain treatment strategies.
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